High-Sensitivity Cardiac Troponin T Reporting, Clinical Outcomes, and Health Care Resource Use

Mau T Nguyen1,2,3, Kristina Lambrakis4,5, Sam Lehman4,5

  • 1Vascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

JAMA Network Open
|October 15, 2024
PubMed

Insights

Reporting high-sensitivity cardiac troponin T (hs-cTnT) to the lowest limit of quantification did not increase myocardial infarction diagnoses or invasive procedures. This practice may improve hospital resource use without causing patient harm.

Area of Science:

  • Cardiology
  • Clinical Diagnostics
  • Health Services Research

Background:

  • Clinical guidelines recommend high-sensitivity cardiac troponin (hs-cTn) assays.
  • Concerns exist regarding hs-cTn use, including resource utilization and diagnostic rates.
  • The impact of reporting hs-cTn T (hs-cTnT) to the lowest limit of quantification (LLOQ) on clinical outcomes requires characterization.

Purpose of the Study:

  • To assess the association between reporting hs-cTnT to the LLOQ versus conventional reporting.
  • To evaluate clinical outcomes, including myocardial infarction (MI) diagnoses, procedural rates, and resource use.

Main Methods:

  • A historically controlled cohort study design was employed in South Australia.
  • Patients (≥18 years) presenting to public emergency departments (EDs) between Feb 2020-Feb 2021 were included.
  • Inverse probability treatment weighting was used to adjust for patient characteristics.

Main Results:

  • A total of 40,921 patients were analyzed.
  • Unmasked hs-cTnT reporting was linked to higher ED discharge rates (45.2% vs 39.0%) and shorter hospital stays (7.68 vs 7.92 hours).
  • No significant differences were observed in MI diagnoses, coronary angiography, percutaneous coronary intervention, or coronary artery bypass graft rates.

Conclusions:

  • Unrestricted hs-cTnT reporting to the LLOQ was not associated with increased MI diagnoses or invasive procedures.
  • This reporting practice may be associated with improved hospital resource utilization.
  • No increase in patient harm was detected at 12 months, suggesting potential benefits in efficiency.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
105
Acute Coronary Syndrome III: Diagnostic studies01:30

Acute Coronary Syndrome III: Diagnostic studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
3
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
61
Acute Coronary SyndromeI: Introduction01:30

Acute Coronary SyndromeI: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
3
Acute Coronary Syndrome II: Pathophysiology and clinical manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and clinical manifestations

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
3
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
3